Back to top
more

TransMedics Group (TMDX)

(Real Time Quote from BATS)

$86.44 USD

86.44
853,903

+0.94 (1.10%)

Updated Nov 8, 2024 02:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

TransMedics (TMDX) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

TransMedics (TMDX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

TransMedics (TMDX) delivered earnings and revenue surprises of 37.50% and 35.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 5.48% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights TransMedics, PROCEPT BioRobotics and Sensus Healthcare

by Zacks Equity Research

TransMedics, PROCEPT BioRobotics and Sensus Healthcare are part of the Zacks top Analyst Blog Highlights.

Indrajit Bandyopadhyay headshot

3 Resilient Medical Stocks to Watch as Rate Hikes Continue

by Indrajit Bandyopadhyay

Here we discuss three Medical-Instruments stocks - TMDX, PRCT & SRTS - that continued to grow in the first nine months of 2022 even though three Fed rate hikes dragged broader indices down.

    TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    TransMedics (TMDX) delivered earnings and revenue surprises of -28.13% and 26.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    TransMedics (TMDX) delivered earnings and revenue surprises of -8.57% and 55.34%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    TransMedics (TMDX) Soars 9.9%: Is Further Upside Left in the Stock?

    by Zacks Equity Research

    TransMedics (TMDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

    TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    TransMedics (TMDX) delivered earnings and revenue surprises of -6.98% and 26.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Pacific Biosciences (PACB) delivered earnings and revenue surprises of -7.14% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    TransMedics (TMDX) Reports Q3 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    TransMedics (TMDX) delivered earnings and revenue surprises of -46.88% and -30.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

    by Zacks Equity Research

    Sector ETF report for XHE

    Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

    by Zacks Equity Research

    Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in the Pharmaceutical segment.

    TransMedics (TMDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

    by Zacks Equity Research

    TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

    by Zacks Equity Research

    Sector ETF report for XHE

    TransMedics (TMDX) Receives FDA Nod for OCS Heart System

    by Zacks Equity Research

    TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.

    Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

    by Zacks Equity Research

    Sector ETF report for XHE

    TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    TransMedics (TMDX) delivered earnings and revenue surprises of -44.44% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Will TransMedics (TMDX) Report Negative Earnings Next Week? What You Should Know

    by Zacks Equity Research

    TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

    by Zacks Equity Research

    Sector ETF report for XHE

    TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    TransMedics (TMDX) delivered earnings and revenue surprises of -3.57% and 1.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    TransMedics (TMDX) delivered earnings and revenue surprises of 8.00% and 24.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    Sriparna Ghosal headshot

    3 Beaten-Down MedTech Stocks Set to Stage a Comeback in 2021

    by Sriparna Ghosal

    Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.

    TransMedics (TMDX) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    TransMedics (TMDX) delivered earnings and revenue surprises of 42.42% and 19.58%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

    Will TransMedics (TMDX) Report Negative Earnings Next Week? What You Should Know

    by Zacks Equity Research

    TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.